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(SERPINA1) gene in chronic liver disease: 
a case control study
Karin F Kok*, René H te Morsche, Martijn GH van Oijen, Joost PH Drenth
Abstract
Background: Alpha-1 antitrypsin (A1AT) deficiency, caused by the Z allele (p.E342K) and S allele (p.E264V) in the 
SERPINA1 gene, can induce liver and pulmonary disease. Different mechanisms appear to be responsible for the 
pathogenesis of these divergent disease expressions. The c.-1973T >C polymorphism located in the SERPINA1 
promoter region is found more frequent in A1AT deficiency patients with liver disease compared to patients with 
pulmonary disease, but data are lacking regarding contribution to the development of liver diseases caused by 
other aetiologies.
Aim: To study the prevalence of c.-1973T >C, Z allele and S allele in a cohort of patients with liver disease of 
various aetiologies compared with healthy controls and to evaluate its effect on disease progression.
Methods: A total of 297 patients with liver disease from various aetiologies and 297 age and gender matched 
healthy controls were included. The c.-1973T >C polymorphism and Z and S alleles of the SERPINA1 gene were 
analyzed by real-time PCR.
Results: c.-1973T >C was similarly distributed between patients with liver disease of various origins and healthy 
controls. Furthermore, the distribution of c.-1973T >C was independent from aetiology subgroup. In patients with 
liver disease mean ages at of onset of liver disease were 44.4, 42.3 and 40.7 years for the c.-1973 T/T, T/C and C/C 
genotype respectively (NS). S allele heterozygosity was increased in patients with drug induced liver injury (DILI), 
(OR 4.3; 95%CI 1.1-17.2).
Conclusion: In our study, c.-1973T >C polymorphism was not a risk factor for liver disease of various aetiologies. In 
addition, S allele heterozygosity m ight contribute to the development of DILI.
Background
A lpha-1  an titry p s in  (A1AT) deficiency is a h e red ita ry  
d isease and  can  in d u ce  en d -o rg an  dam age caused  by 
defec tive  A 1A T  p ro te in  p ro c e ss in g . L iver d isease  in  
A 1A T deficiency is caused by hepatic  accum ulation  o f 
the A1AT pro te in  and pulm onary  disease is induced  by 
an im paired  p ro tec tio n  against n eu tro p h il elastase due 
to  d ecreased  se ru m  A 1A T [1,2]. T h e  A 1A T p ro te in  is 
encoded  by the  pro tease inh ib ito r (Pi) locus located  on 
c h ro m o so m e  14q32.1  (SERPINA1 gene). In  W e s te rn
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Europe, A 1A T deficiency m ost com m only  resu lts from  
p re se n c e  o f 2 g en e tic  v a r ia n ts  p.E342K  (d e n o te d  as 
Z allele) an d  p.E264V  (co m m o n ly  re fe rre d  to  as th e  
S a lle le )[3]. L iver d isease  in  A 1A T  d efic ien cy  h as  a 
b im odal p resen ta tion  affecting ch ildren  in  neonata l life
[4] and, less com monly, adults in  late m iddle life[5].
It is unclea r w hy A 1A T deficiency leads to  liver d is­
ease in  som e p a tie n ts  an d  lu n g  d isease  in  o th e rs . I t 
appears th a t environm ental factors are in  p art responsi­
ble for th is difference. P u lm onary  disease develops p re ­
ferably in  hom ozygous Pi ZZ persons w ho are tobacco 
sm okers o r are exposed to  airw ay ir rita n ts [6]. Indeed, 
sm oking is an established risk factor for lung disease as
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A 1A T  d e fic ien t sm o k e rs  w ill develop  em p h y sem a at 
considerable younger age, while non-sm okers are at risk 
for liver disease developing later in  life [7]. Some 32-37% 
o f A 1A T defic ien t n o n -sm o k in g  p a tien ts  w ill die as a 
result of A1AT deficiency induced liver disease[8].
A p art from  env ironm enta l factors th e re  is som e evi­
dence  th a t  g en e tic  fac to rs  m odify  th e  risk  fo r A 1A T 
deficiency related  end-organ  dam age. For exam ple, 72% 
o f sib lings of p ro b an d s  w ith  A 1A T defic iency  re la ted  
liver disease suffered from  liver disease, w hich was con­
c o rd a n t fo r sev erity  in  29%, w hile  28% h ad  no  liver 
involvem ent[9]. This suggests presence of genetic m odi­
fiers. In d e e d  a re c e n t s tu d y  id e n tif ied  a novel single 
nucleotide polym orphism  (SNP) g.126076T >C (c.-1973T 
>C; rs8004738) in  the p ro m o te r region of SERPINA1. It 
appeared th a t the SNP was enriched (15.5%) in a cohort 
o f A 1A T Pi ZZ hom ozygotes w ith  liver disease relative 
to  those w ith pulm onary disease (6.5%)[10].
As a resu lt of the  above-m en tioned  observa tions we 
h y p o th esized  th a t  c.-1973T >C p o ly m o rp h ism  affects 
su sc e p tib ility  fo r th e  p ro g re ss io n  of live r d isease  in  
patien ts w ith liver disease of various aetiologies. T h ere ­
fo re  we in v e s tig a ted  th e  as so c ia tio n  o f c.-1973T  >C, 
p.E342K (Z allele) and p.E264V (S allele) polym orphism s 
in  a c o h o r t o f p a t ie n ts  w ith  live r d isease  of v a rio u s  
aetio logies com pared  w ith  healthy  con tro ls  and evalu­
ated its consequence on course of disease.
Methods
Patients
W e recru ited  patien ts w ith  various liver disorders, visit­
ing the ou tpatien t clinic of the D epartm ent of G astroen­
te ro lo g y  an d  H ep a to lo g y  o f th e  R ad b o u d  U n iv ersity  
N ijm egen M edical C enter. In  addition , age and gender 
m a tch e d  p e rso n s  w ho w ere u n re la te d  to  o u r p a tien ts  
served  as h ea lth y  con tro ls . In  th e  p a tie n t p o p u la tio n , 
clinical and dem ographic data including age, sex, age at 
first p resen ta tion  of liver disease, aetiology of liver d is­
ease and presence or absence of cirrhosis were obtained. 
T he absence of liver disease in  ou r con tro l popu la tion  
was established on the basis of se lf-reporting  and none 
of the patien ts used any m edication. W hole blood sam ­
ples w ere sto red  at -20°C. A ltogether the study popu la­
tio n  com prised  297 patien ts w ith  various aetiologies of 
liver disease and 297 controls. Clinical and dem ographic 
data  are given in  T able 1. T he s tudy  w as approved  by 
the local ethical com m ittee (M edical E thical C om m ittee 
of th e  R adboud U niversity  N ijm egen  M edical C en ter) 
and all subjects gave their inform ed consent.
Laboratory
DN A  was isolated from  peripheral blood using the H igh 
Pure PCR T em plate p repara tion  kit (Roche, M annheim , 
G erm an y ). T h e  c.-1973T >C (rs8004738), p.E342K
Table 1 Baseline characteristics of patients and controls.
Patients Controls P-
value
(n = 297) (n = 297)
Male (%) 168 (57)
Mean age (range) 51.4 yrs (19-
85)
Mean age at onset liver disease 43 yrs (7-82)
(range)
Cirrhosis (%) 69 (23)
Cause of liver disease (%)
-HCV 129 (43)
-AIH/PBC/PCS 53 (18)
-HBV 50 (17)
-Alcoholic liver disease 21 (7)
-NASH/metabolic 16 (5)
-Cryptogenic 13 (4)
-Drug induced liver injury 11 (4)
-Vascular 4 (1)
163 (55)
85)
0.74
HCV = hepatitis C virus, AIH/PSC/PBC = autoimmune hepatitis/primary biliary 
cirrhosis/primary sclerosing cirrhosis, HBV = hepatitis B virus, NASH = non­
alcoholic steato hepatitis
(Z allele; c .1024G  > A; rs28929474) an d  p.E264V  
(S allele; c.791A  > T; rs17580) po ly m o rp h ism s of the  
SERPINA1 gene w ere analyzed by real-tim e polym erase 
chain  reaction  (PCR) using a dual-color, allele-specific 
d iscrim ination assay w ith  fluorescent labelled probes on 
the  iC ycler iQ  M u ltico lo u r rea l-tim e d e tec tio n  system  
(Bio-Rad Laboratories Inc, H ercules, CA, USA). P rim er 
and probe sequences (Sigma, St Louis, M O , USA) used 
for PCR and real tim e detec tion  are listed in  additional 
file 1. All of the genotyping results in  the contro l popu ­
lation w ere in  the H ardy-W einberg  equilibrium . H aplo- 
ty p es an d  d ip lo ty p es  w ere  d e te rm in e d  u s in g  th e  
Partition-Ligation-Expectation-M axim ization (PLEM) 1.0 
software [11 ].
Statistical analysis
Baseline characteristics, differences in  allele frequency, 
diplotypes and haplotypes w ere analyzed using s tu d en t 
t-tests, P earson ch i-squared  te s t and Fisher's exact test 
w hen appropriate. O dds Ratio's (OR) were calculated for 
the association betw een the studied polym orphism s and 
the presence of liver disease. In  add ition  we calculated 
O R 's for th e  association  betw een the  3 polym orphism s 
and all d ifferent subgroup aetiologies. W e analyzed dif­
ferences in  age at onse t of liver disease betw een  the  3 
different c.-1973 genotypes using ANOVA. All statistical 
analyses were perform ed using G raphPad Prism  V ersion
4.02 (G rap h P ad  Softw are Inc., San D iego, CA, USA). 
A  tw o-sided  p-value of <  0.05 w as considered  s ta tis ti­
cally significant. Post-hoc pow er calculation show ed the 
s tu d y  b e in g  a d e q u a te  p o w ered  (8 8%) to  n eg a te  o u r
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hypothesis th a t c.-1973T >C is associated w ith  liver dis­
ease of various aetiologies (a  = 0.05, difference in  group 
p ro p o rtio n s  10% (20% and  30%)). P ow er ca lcu la tio n s 
w ere  p e rfo rm e d  u s in g  n Q u e ry  A d v iso r 4 .0  so ftw are  
(Statistical Solu tions Ltd, Cork, Ireland). Linkage d ise­
qu ilibrium  (LD) values w ere perform ed w ith  Haploview  
4.0 software.
Results
C polymorphism",1,0,1,0,0pc,0pc,0pc,0pc>c.-1973T > C 
polymorphism
T h e  c.-1973T >C p o ly m o rp h ism  d is tr ib u t io n  in  297 
patients w ith  liver disease due to  various aetiologies was 
in  line w ith  297 h ea lth y  co n tro ls . (c.-1973: T /T  32%, 
T /C  44% and  C /C  24% in  p a tien ts  and  T /T  30%, T /C  
50% and C /C  20% in controls). (Figure 1) W e found no 
association  of the  c.-1973T >C po lym orphism  w ith  any 
of th e  d is t in c t  live r d iseases  in v e s tig a ted . N ex t, we 
observed  th a t  m ean  age a t o n se t of liver d isease w as 
non-significantly  lower in  patients w ith  the c.-1973 C /C  
allele, as m ean  ages of onse t of liver disease w ere 44.4 
(T /T ), 42 .3  (T /C ) an d  40 .7  (C /C ) years. (F igure  2) 
F urther, possession  of c.-1973T >C po lym orph ism  had 
no influence on the presence of cirrhosis.
Z (p.E342K) allele and S (p.E264V) allele heterozygosity
W e observed a sim ilar Z allele and S allele heterozygos­
ity rate in patients and controls (Z allele: 3.0% and 4.7%; 
S allele: 6.7% and 8.0%). The d istribution of Z allele h e t­
erozygosity was sim ilar am ong all liver diseases of var­
ious aetiologies. In  contrast, S allele heterozygosity  was 
m o re  fre q u en tly  p re se n t in  d rug  in d u c ed  liver in ju ry  
(DILI) com pared w ith  healthy controls (11 patients, 27% 
vs 8%; OR 4.27; 95%CI 1.06-17.15). A  total of 8 wildtype 
p a tie n ts  developed  DILI likely due to  clavu lan ic acid 
(n = 3), azatioprine, sulfasalazine, pantoprazole, m e th o ­
trexate and quetiapine; addionally, the S allele heterozy­
g o te s  h ad  D ILI ca u se d  by a n a e s th e tic  c o m p o u n d s
Patients Controls
Figure 1 Distribution of the c.-1973T > C  genotypes in 297 
patients with liver disease of various aetiologies and 297 
controls.
C.-1973T>C
Figure 2 Age at onset of liver disease in 297 patients arranged 
to the different c.-1973T >C  genotypes.
( iso f lu ra n e /n e s to n a l) , c lavu lan ic  acid  an d  ce lecox ib . 
Lastly, age at onset of liver disease was ind ep en d en t of 
Z o r S allele  h e te ro zy g o s ity  as m e an  ages w ere  48.3 
(Z allele), 43.2 (S allele) and 42.4 (wildtypes) years.
Haplotyping/diplotyping
B ased on  th e  3 po ly m o rp h ism s tested , hap lo type  and 
diplotype analysis w ere perform ed. A  to ta l of 11 diplo- 
types could be distinguished. W e could n o t detect differ­
ences in  diplo types betw een  pa tien ts  w ith  liver disease 
of various etiologies and controls. O nly the CTG haplo- 
type w as m ore  f re q u e n t fo u n d  in  p a tie n ts  w ith  DILI, 
accord ing  to  the  above-described  associa tion  betw een  
S allele heterozygosity and DILI. (Table 2) Finally, link­
age disequilibrium  (LD) between the 3 SERPINA1 alleles 
was absent. T h is w as tru e  for p a tien ts  as well as co n ­
trols. (Figure 3)
Table 2 Diplotypes in patients with liver disease of 
various aetiology and healthy controls
Diplotype Controls (% )
n = 297
Patients (% ) 
n = 297
CAG/TAG
TAG/TAG
CAG/CAG
CTG/TAG
CAG/CTG
TAG/TAA
CAG/TAA
TAG/TTG
CTG/TAA
CTG/CTG
CAG/CAA
130 (43.8) 
78 (26.3) 
51 (17.2) 
11 (3.7)
8 (2.7)
8 (2.7)
5 (1.7)
4 (1.3)
1 (0.3)
1 (0.3)
112 (37.7) 
93 (31.3) 
63 (21.2) 
12 (4.0)
7 (2.4)
2 (0.7)
6 (2.0)
1 (0.3)
1 (0.3)
Order of alleles: c.-1973T >C- c.791A > T - c.1024G > A/c.-1973T >C- c.791A > T 
- c.1024G > A (mutations in bold)
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Figure 3 Linkage disequilibrium (LD) plot across the SERPINA1 gene. Patients. Controls. The box at the top indicates the SERPINA1 gene 
with the 3 investigated SNP's (1 = p.E342K, 2 = p.E264V and 3 = C.-1973T >C). The LD plot is based on the measurement of R2 (values x 0.01). 
Each diamond indicates the pair wise magnitude of LD. (LD: linkage disequilibrium is the non-random association of alleles at two or more loci. 
LD describes a situation in which some combinations of alleles or genetic markers occur more or less frequently in a population than would be 
expected from a random formation of haplotypes from alleles based on their frequencies.)
Discussion
W e show  th a t the  d is tr ib u tio n  o f SERPINA1 c.-1973T 
>C in  patients w ith  liver disease from  various aetiologies 
is sim ilar co m p ared  to  hea lthy  co n tro ls . T h e  genotype 
frequenc ies in  the  p a tie n t and  c o n tro l g roups w ere in 
line w ith  th o se  from  th e  H apM ap  da tabase  (T T  30%, 
T /C  45% and C /C  25%) [12]. M oreover, we found  th a t 
th e  d is tr ib u tio n  of c.-1973T >C is in d e p e n d e n t from  
aetiology of the liver disease. W e also exam ined w hether 
th e  c.-1973T >C p o ly m o rp h ism  affec ted  age a t o n se t 
o f live r d isease . W e fo u n d  a n o n -s ig n if ic a n t low er 
age at onse t in  patien ts  w ith  th e  c.-1973 C /C  genotype 
co m p ared  to  o th e r  c.-1973 genotypes. In  add ition , we 
could n o t dem onstrate an association of c.-1973T >C on 
severity  o f liver disease e.g. c irrhosis. W e also investi­
ga ted  o th e r  SERPIN A1 v arian ts  an d  fo u n d  th a t  th e re  
w as no  in c re a se d  p rev a len c e  o f Z  an d  S a lle les in  
p a tien ts  w ith  liver d isease of various aetio log ies com ­
pared  w ith  healthy  contro ls, even th o u g h  we observed 
an enrichm ent of S allele heterozygosity in  patients w ith 
DILI.
O th e r  in v e s tig a to rs  have s tu d ie d  th e  p re se n c e  of 
c.-1973T >C and A1AT deficiency and chronic obstruc­
tive pulm onary disease (COPD). Chappell et al. reported  
an e n r ic h m e n t o f c.-1973T >C in  hom ozygous Pi ZZ 
n eona tes  w ith  hepa titis  (15.5%) com pared  to  hom ozy­
gous Pi ZZ contro ls (adults w ith  COPD and unaffected 
sub jects) (6.5% )[10]. Since o u r s tu d y  p o p u la tio n  c o n ­
s is ted  for a large ex ten t o f p a tien ts  and  co n tro ls  w ith  
the Pi M M  genotype (wildtypes) and hardly any subjects 
w ith  Z and S allele heterozygosity, we canno t com pare 
our data w ith  the results of the above m en tioned  study. 
A n o th e r  s tu d y  sh o w ed  a d ec re a se d  p rev a len c e  o f 
c.-1973T >C in  pa tien ts  w ith  CO PD  (48.7%) com pared  
to  controls (52.2%), suggesting a protective effect against 
C O PD [13]. It m ight be possible th a t c.-1973T >C influ­
ences th e  genesis of liver disease in  childhood, in  line 
w ith  a recen tly  published rep o rt im plicating  th a t a var­
ia n t o f th e  e n d o p la sm ic  r e t ic u lu m  m a n n o s id a se
I (ERM anI) gene is assoc ia ted  w ith  an early  o n se t of 
en d -s ta g e  liver d isease in  p a tie n ts  w ith  hom ozygous 
(Pi ZZ) A1AT deficiency[14].
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O ur data w ere in contrast w ith o ther reports as Z and
S allele heterozygosity  w ere previously  associated  w ith  
(end-stage) liver disease due to  HCV, alcoholic liver dis­
ease an d  c ry p to g e n ic  c irrh o s is  [15- 19] an d  n o t w ith  
DILI. W e found  a h igher frequency  of S allele h e te ro ­
zygosity in  DILI patients. Indeed, experim ental evidence 
supports  a re la tion  betw een A1AT deficiency and DILI 
as adm in istra tion  of indom ethacin  in  a hom ozygous Pi 
ZZ m ouse m odel leads to  increased  hepatic  injury [20] 
and  a case re p o rt described  p ro ch lo rp eraz in e  induced  
liver in ju ry  in  a hom ozygous (Pi ZZ) A 1A T defic ien t 
patient [2 1].
W e co u ld  n o t d e m o n s tra te  an  asso c ia tio n  b e tw een  
c.-1973T >C and the  p resence of cirrhosis. T here  have 
b ee n  sev era l g e n e tic  case c o n tro l s tu d ie s  th a t  have 
a ttem p ted  to  detec t associations betw een genetic varia­
tions and liver fibrosis. For example, the com bination of 
ang io tensinogen  (ATG) gene v arian t c.1-44 and tra n s ­
fo rm in g  g ro w th  fac to r b e ta  (TG FP1) p.R 25P is a sso ­
ciated  w ith  advanced hepatic  fibrosis in  obese patien ts 
w ith  n o n  a lcoho lic  fa tty  liver d isease [22 ] b u t n o t in  
p a tie n ts  w ith  o th e r  ch ro n ic  liver d iseases[23]. Lastly, 
m a tr ix  m e ta llo p ro te in a se  (M M P)-7(A sp-137) confers 
risk of liver cirrhosis[24].
O ur s tudy  com es w ith  lim ita tions. O u r co h o rt could 
have suffered from  selection bias due to  patien t rec ru it­
m e n t in  a te rtia ry  referra l cen tre . T he s tren g th  of our 
s tudy  is the  sufficiently  pow er to  negate  a 1 0% differ­
ence in  p revalence of th e  c.-1973T >C po ly m o rp h ism  
b e tw e en  g ro u p s . H ow ever, th e  s tu d y  lacks p o w er to  
dem onstra te  sm aller differences and to  perform  a th o r­
o u g h  su b g ro u p  analysis. F u r th e r  re se a rc h  reg a rd in g  
c.-1973T >C shou ld  include hom ozygous Pi ZZ adults 
w ith  liver disease to  evaluate w hether c.-1973T >C is a 
risk factor for a hepatic expression of A1AT deficiency.
Conclusion
W e dem onstra ted  that, in  our study, c.-1973T >C poly­
m orph ism  was n o t associated w ith  liver disease of var­
io u s  ae tio lo g ies . In  ad d itio n , S allele  h e te ro zy g o s ity  
m ight be a risk factor for the genesis of DILI.
Additional file 1: Overview of primers and probes used for real 
time PCR reactions.
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